Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pneumonia due to Staphylococcus aureus infection

B al-Ujayli1, D A Nafziger, L Saravolatz

  • 1Henry Ford Hospital, Detroit, Michigan, USA.

Clinics in Chest Medicine
|March 1, 1995
PubMed
Summary

Staphylococcus aureus pneumonia is a serious ICU infection. Effective treatment relies on susceptibility testing, with beta-lactams as first-line therapy, and vancomycin for resistant strains, though mortality remains high.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel anticoagulants for stroke prevention in patients with atrial fibrillation.

Cardiovascular drugs and therapy·2014
Same author

Use of octreotide, a long-acting somatostatin analogue, in the treatment of chylothorax of idiopathic etiology.

Minerva chirurgica·2006
Same author

Antimicrobial activity of BMS 284756, a novel des-fluoro (6) quinolone and seven fluoroquinolones against Streptococcus pneumoniae.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2001
Same author

Linezolid for treatment of vancomycin-resistant enterococcal peritonitis.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2001
Same author

Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.

The Journal of antimicrobial chemotherapy·2001
Same author

Staphylococcus epidermidis with intermediate resistance to vancomycin: elusive phenotype or laboratory artifact?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Critical Care Medicine

Background:

  • Staphylococcus aureus is a leading cause of intensive care unit (ICU) pneumonia.
  • Its toxins and enzymes cause significant lung tissue damage.
  • Clinical presentation and diagnosis of S. aureus pneumonia are often indistinguishable from other pathogens.

Purpose of the Study:

  • To review the diagnostic challenges and therapeutic strategies for Staphylococcus aureus pneumonia.
  • To emphasize the importance of antimicrobial susceptibility testing in guiding treatment.
  • To discuss the limitations of current therapies and high mortality rates.

Main Methods:

  • Literature review of Staphylococcus aureus pneumonia.
  • Analysis of diagnostic criteria and clinical features.
  • Evaluation of therapeutic guidelines and outcomes.

Main Results:

  • Clinical diagnosis of S. aureus pneumonia is difficult and shares limitations with other bacterial pneumonias.
  • Antimicrobial susceptibility testing is crucial for effective therapy selection.
  • Beta-lactam agents are the first-line treatment, with vancomycin reserved for beta-lactam-resistant Staphylococcus aureus (BRSA) or intolerance.

Conclusions:

  • Despite available treatments, mortality for S. aureus pneumonia remains high.
  • Hematogenous spread of infection is associated with particularly poor outcomes.
  • Further research into novel therapeutic approaches is warranted.

Related Experiment Videos